, Volume 175, Issue 1–2, pp 129–134 | Cite as

Micafungin for Candida Albicans Pacemaker-Associated Endocarditis: A Case Report and Review of the Literature

  • Carlo Tascini
  • Maria Grazia Bongiorni
  • Enrico TagliaferriEmail author
  • Antonello Di Paolo
  • Sarah Flammini
  • Ezio Soldati
  • Alessandro Leonildi
  • Andrea Di Cori
  • Francesco Menichetti


We report on the treatment with micafungin of a pacemaker-associated endocarditis due to Candida albicans. Antifungal therapy was able to reduce vegetation size from 5 to 1 cm making possible the transvenous removal of the device without a high risk of pulmonary embolism. Noteworthy, a high micafungin concentration was documented into the lead vegetation (10 μg/g of vegetation tissue) and this may have contributed to the striking size reduction of vegetation.


Micafungin Candida Endocarditis Pacemaker 



The authors wish to thank the nurse staff and technicians at the Santa Chiara University Hospital, Pisa.

Conflict of interest

In the past 2 years, Dr Carlo Tascini has been paid for lectures on behalf of Pfizer, Novartis, Merck and Astellas.


  1. 1.
    Eggiman P, Waldvogel F. Pacemaker and defibrillator infection. In: Waldvogel F, Bisno A, editors. Infections associated with indwelling medical devices. Washington: ASM press; 2000. p. 247–64.Google Scholar
  2. 2.
    Mond HG, Proclemer A. The 11th World Survey of Cardiac Pacing and Implantable Cardioverter-Defibrillators: calendar Year 2009—A World Society of Arrhythmia’s Project. Pacing Clin Electrophysiol. 2011;34(8):1013–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Bluhm G. Pacemaker infections. 2-year follow-up of antibiotic prophylaxis. Scand J Thorac Cardiovasc Surg. 1985;16:65–70.CrossRefGoogle Scholar
  4. 4.
    Lay KK, Fontecchio SA. Infections associated with implantable cardioverter defibrillators placed trasvenously and via thoracotomies: epidemiology, infection control, and management. Clin Infect Dis. 1998;27:265–9.CrossRefGoogle Scholar
  5. 5.
    Kearney RA, Eisen HJ, Wolf JE. Nonvalvular infections of the cardiovascular system. Ann Intern Med. 1994;121:219–30.PubMedGoogle Scholar
  6. 6.
    Karchmer AW. Infections of prosthetic valves and intravascular devices. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 911–3.Google Scholar
  7. 7.
    Arber N, Pras E, Copperman Y, Schapiro JM, Meiner V, Lossos IS, et al. Pacemaker endocarditis: report of 44 cases and review of the literature. Medicine (Baltimore). 1994;73:299–305.Google Scholar
  8. 8.
    Tascini C, Bongiorni MG, Gemignani G, Soldati E, Leonildi A, Arena G, et al. Management of cardiac device infections: a retrospective survey of a non-surgical approach combining antibiotic therapy with transvenous removal. J Chemot. 2006;18(2):157–63.Google Scholar
  9. 9.
    Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121(3):458–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Camus C, Leport C, Raffi F, Michelet C, Carteier F, Vilde JL. Sustained bacteraemia in 26 patients with a permanent endocardial pacemaker: assessment of wire removal. Clin Infect Dis. 1993;17:46–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Choo MH, Holmes DR Jr, Gersh JB, Maloney JD, Merideth J, Pluth JR, Trusty J. Permanent pacemaker infections: characterization and management. Am J Cardiol. 1981;48:559–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Rettig G, Doenecke P, Sen S, Volomer I, Bette L. Complications with retained transvenous pacemaker electrodes. Am Heart J. 1979;98:587–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Vogt PR, Sagdic K, Lachat M, Candinas R, von Segesser LK, Turina MI. Surgical management of infected permanent transvenous pacemaker system: ten years experience. J Card Surg. 1996;11:180–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Byrd CL, Schwartz SJ, Hedin NB, Goode LB, Fearnot NE, Smith HJ. Intravascular lead extraction using locking stylets and sheaths. Pacing Clin Electrophysiol. 1990;13:1871–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Manolis AS, Maounis TN, Chiladakis J, Vassilikov V, Melita-Manolis H, Cokkinos DV. Successful percutaneous extraction of pacemakers leads with a novel (vascoextor) pacing lead removal system. Am J Cardiol. 1998;81:935–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Wilhelm MJ, Schmid C, Hammel D, Kerber S, Loick HM, Hermann M, Scheld HH. Cardiac pacemaker infection; surgical management with or without extracorporeal circulation. Ann Thorac Surg. 1997;64:1707–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith MC, Love CJ. Extraction of trans-venous pacing and ICD leads. Pacing Clin Electrophysiol. 2008;31:736–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Baddour LM, Cha YM, Wilson WR. Clinical practice. Infections of cardiovascular implantable electronic devices. N Engl J Med. 2012;367(9):842–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Bongiorni MG, Tascini C, Tagliaferri E, Di Cori A, Soldati E, Leonildi A, Zucchelli G, Ciullo I, Menichetti F. Microbiology of cardiac implantable electronic device infections. Europace. 2012;14(9):1334–9.Google Scholar
  20. 20.
    Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner S, Baddour LM. Management and outcome of permanent and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49:1851–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Halawa A, Henry PD, Sarubbi FA. Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines. Mycoses. 2011;54(4):e168–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Talarmin JP, Boutoille D, Tattevin P, Abgueguen P, Ansart S, Roblot F, Raffi F. Candida endocarditis: role of new antifungal agents. Mycoses. 2009;52(1):60–6. Epub 2008 May 21.PubMedCrossRefGoogle Scholar
  24. 24.
    Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, Rizzi M, Suter F, Utili R, Viscoli C, Venditti M. Italian Study on Endocarditis. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore). 2009;88(3):160–8.CrossRefGoogle Scholar
  25. 25.
    d’Enfert C. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets. 2006;7:465–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Updat. 2004;7:301–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46:3591–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother. 2008;62:153–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2008;52:2242–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Pai MP, Samples ML, Mercier RC, Spilde MN. Activity and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother. 2008;52:2367–76.PubMedCrossRefGoogle Scholar
  32. 32.
    Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002;46:3634–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Serena C, Mariné M, Quindós G, Carrillo AJ, Cano JF, Pastor FJ, Guarro J. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother. 2008;52:1529–32.PubMedCrossRefGoogle Scholar
  34. 34.
    Shuford JA, Piper KE, Steckelberg JM, Patel R. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn Microbiol Infect Dis. 2007;57:277–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Norice CT, Smith FJ Jr, Solis N, Filler SG, Mitchell AP. Requirement for Candida albicans Sun41 in biofilm formation and virulence. Eukaryot Cell. 2007;6:2046–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Pai MP. Antifungal combinations against simulated Candida albicans endocardial vegetations. Antimicrob Agents Chemother. 2009;53(6):2629–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71:11–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Salmi D, Bhat A, Corman L, Raff G, Satake N. Diagnostic challenges in native valve fungal endocarditis producing a massive septic pulmonary embolus. Nihon Ishinkin Gakkai Zasshi. 2010;51(4):207–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Chopra T, Bhargava A, Kumar S, Chopra A, Dhar S, Afonso L, Sobel JD. Candida kefyr endocarditis in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci. 2010;339(2):188–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother. 2001;45:3322–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother. 2011;17:731–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev. 2004;17:268–80.PubMedCrossRefGoogle Scholar
  43. 43.
    Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Russomanno J, Shore E, Kuti JL. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother. 2009;53:1218–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Nakagawa Y, Ichii Y, Saeki Y, Kodaka M, Suzuki K, Kishino S. Plasma concentration of micafungin in patients with hematologic malignancies. J Infect Chemother. 2007;13:39–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Carlo Tascini
    • 1
  • Maria Grazia Bongiorni
    • 2
  • Enrico Tagliaferri
    • 1
    • 4
    Email author
  • Antonello Di Paolo
    • 3
  • Sarah Flammini
    • 1
  • Ezio Soldati
    • 2
  • Alessandro Leonildi
    • 1
  • Andrea Di Cori
    • 2
  • Francesco Menichetti
    • 1
  1. 1.U.O. Malattie InfettiveAzienda Ospedaliera Universitaria PisanaPisaItaly
  2. 2.U.O. Cardiologia IIAzienda Ospedaliera Universitaria PisanaPisaItaly
  3. 3.Divisione di Farmacologia e ChemioterapiaUniversità di PisaPisaItaly
  4. 4.U.O. Malattie InfettiveNuovo Santa Chiara HospitalPisaItaly

Personalised recommendations